IDEXX Laboratories Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 2, 2026 results vs estimates
IDEXX Laboratories Inc Forecast
IDEXX Laboratories Inc short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is positive (5 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 25.4% a year, a typical one-standard-deviation range is 555.33–596.63 over a week, 533.67–618.29 over a month and 429.40–722.56 over a year. (Signals as of 1 Nov 2026.)
IDEXX Laboratories Inc Price Chart
IDEXX Laboratories Inc Factors
YoY −32.4%
YoY −30.5%
YoY −35.1%
YoY −32.4%
YoY −30.4%
YoY +75.9%
YoY +48.0%
YoY −22.3%
YoY −14.3%
YoY −25.6%
YoY +5.6%
YoY +8.1%
YoY +19.4%
YoY −27.0%
YoY +28.6%
YoY −16.6%
IDEXX Laboratories Inc fundamentals: income statement, balance sheet & cash flow
IDEXX Laboratories Inc reported revenue of $4.30bn and net income of $1.06bn in FY2025, the year ended 31 December 2025 — revenue up 10.4% and net income up 19.3% on the prior year. Free cash flow was $1.06bn. These figures are as reported in the filings, not restated: 35 fiscal years and 143 quarters of history, back to December 1991. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 4,303.7 | 3,897.5 | 3,661.0 | 3,367.3 | 3,215.4 |
| Cost of revenue | 1,644.1 | 1,518.6 | 1,471.0 | 1,363.0 | 1,325.9 |
| Gross profit | 2,659.6 | 2,378.9 | 2,190.0 | 2,004.3 | 1,889.4 |
| Research & development | 251.2 | 219.8 | 191.0 | 254.8 | 161.0 |
| Selling, general & admin. | 1,048.3 | 1,030.8 | 901.9 | 850.8 | 796.4 |
| Operating income | 1,360.0 | 1,128.3 | 1,097.1 | 898.8 | 932.0 |
| EBITDA | 1,507.6 | 1,275.8 | 1,097.1 | 1,010.7 | 1,036.6 |
| Interest expense | 38.3 | 31.2 | 36.0 | 38.8 | 29.4 |
| Pre-tax income | 1,324.2 | 1,109.8 | 1,061.2 | 860.0 | 902.7 |
| Income tax | 264.7 | 222.0 | 216.1 | 180.9 | 157.8 |
| Net income | 1,059.5 | 887.9 | 845.0 | 679.1 | 744.8 |
Download IDEXX Laboratories Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.IDXX.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on IDEXX Laboratories Inc
Explore MacroFinance macro & markets research and analysis.
IDEXX Laboratories Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to IDEXX Laboratories Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow IDEXX Laboratories Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About IDEXX Laboratories Inc (United States)
IDEXX Laboratories Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is IDEXX Laboratories Inc?
What is the latest IDEXX Laboratories Inc price?
Is IDEXX Laboratories Inc in an uptrend?
How volatile is IDEXX Laboratories Inc?
What factors affect IDEXX Laboratories Inc?
Which trading strategies trade IDEXX Laboratories Inc?
How are IDEXX Laboratories Inc returns analysed?
Where can I download free IDEXX Laboratories Inc historical data?
Free IDEXX Laboratories Inc historical data (last 10 years)
Browse or instantly download the last 10 years of IDEXX Laboratories Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.IDXX.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 676.21 |
| 2026-11-19 | 689.65 |
| 2026-11-18 | 698.47 |
| 2026-11-17 | 690.24 |
| 2026-11-16 | 700.65 |
| 2026-11-13 | 704.23 |
| 2026-11-12 | 698.02 |
| 2026-11-11 | 702.59 |
| 2026-11-10 | 696.64 |
| 2026-11-09 | 706.65 |
About this stock
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.